Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06603077 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Avalo Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT06603077 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Avalo Therapeutics. The registered enrollment target is 250 participants, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06603077, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Avalo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AVTX-009 Regimen 1
- DRUG AVTX-009 Regimen 2
Study Locations (20)
Florida
- Clinical Site 1029 - Boca Raton
- Clinical Site 1002 - Coral Gables
- Clinical Site 1015 - Maitland
- Clinical Site 1027 - North Miami Beach
- Clinical Site 1013 - Tampa
California
- Clinical Site 1032 - Northridge
- Clinical Site 1019 - Pomona
- Clinical Site 1009 - Sacramento
- Clinical Site 1034 - Santa Monica
Arizona
- Clinical Site 1022 - Scottsdale
- Clinical Site 1037 - Scottsdale
- Clinical Site 1026 - Tucson
Kentucky
- Clinical Site 1031 - Bowling Green
- Clinical Site 1024 - Murray
Massachusetts
- Clinical Site 1042 - Boston
- Clinical Site 1001 - Boston
District of Columbia
- Clinical Site 1011 - Washington D.C.
Georgia
- Clinical Site 1008 - Savannah
Illinois
- Clinical Site 1014 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06603077
The ClinicalTrials.gov registry entry for NCT06603077 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The listed sponsor is Avalo Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06603077 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06603077 about?
NCT06603077 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa". The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
What is the current status of trial NCT06603077?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2024-09-16. Estimated completion is 2026-04.
What conditions does trial NCT06603077 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06603077?
The interventions under investigation include: Placebo (DRUG), AVTX-009 Regimen 1 (DRUG), AVTX-009 Regimen 2 (DRUG).
Who is sponsoring clinical trial NCT06603077?
This trial is sponsored by Avalo Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06603077 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.